BTAIQ · XBRL financial data

BioXcel Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BTAIQ's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Revenue from contracts with customers	—	—	375	1,380	2,266	642
Cost of goods and services sold	—	—	20	1,260	2,143	164
Research and development	57,995	52,708	91,239	84,326	30,435	30,251
Selling, general and administrative	—	54,227	68,761	83,413	34,492	20,494
General and administrative	24,302	54,227	—	—	—	—
Total operating expenses	82,297	106,935	—	—	—	—
Operating income (loss)	(82,297)	(106,935)	(159,645)	(171,782)	(67,245)	(50,461)
Interest income	155	44	2,528	5,649	2,602	1,066
Interest expense	27	40	8,213	13,314	15,129	16,984
Other income (expense)	—	—	(427)	394	20,173	(3,518)
Income tax expense (benefit)	—	—	—	0	0	0
Net income (loss)	(82,169)	(106,931)	(165,757)	(179,053)	(59,599)	(69,897)
Earnings per share, basic USD per share	(3.79)	(4.05)	(5.92)	(6.15)	(23.51)	(5.73)
Earnings per share, diluted USD per share	(3.79)	(4.05)	(5.92)	(6.15)	(23.51)	(5.73)
Weighted average shares, basic thousands of shares	21,683	26,373	28,015	29,129	2,535	12,208
Weighted average shares, diluted thousands of shares	21,683	26,373	28,015	29,129	2,535	12,208

† Share count changed about 5x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (BTAIQ's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Cash and cash equivalents	213,119	232,968	193,725	65,221	29,854	28,415
Inventory	—	—	1,985	1,991	679	722
Prepaid and other current assets	3,946	2,888	3,067	2,782	5,290	4,028
Total current assets	217,065	236,812	202,868	72,143	37,394	44,685
Property and equipment, net	1,273	1,294	1,084	784	475	175
Right-of-use asset	1,511	1,247	976	688	382	56
Total assets	219,936	239,439	205,853	73,702	38,338	44,916
Accounts payable	3,979	4,678	10,228	13,654	15,990	14,701
Accrued liabilities	7,469	11,492	18,669	12,424	5,762	4,341
Current portion of long-term debt	—	—	—	—	0	24,931
Total current liabilities	11,842	16,667	32,898	27,267	22,233	53,926
Long-term debt	—	—	93,051	100,598	102,508	84,663
Lease liability, non-current	1,398	1,105	786	440	65	0
Total liabilities	13,240	17,772	129,078	130,210	131,439	140,379
Accumulated deficit	(138,857)	(245,788)	(411,545)	(590,598)	(650,197)	(720,094)
Total stockholders' equity	206,696	221,667	76,775	(56,508)	(93,101)	(95,463)
Total liabilities and equity	219,936	239,439	205,853	73,702	38,338	44,916
Common shares outstanding (cover page) thousands of shares	24,573	27,980	29,010	30,577	5,486	27,075

† Share count changed about 5x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (BTAIQ's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Net income (loss)	(82,169)	(106,931)	(165,757)	(179,053)	(59,599)	(69,897)
Stock-based compensation	14,611	19,455	17,337	18,614	6,156	2,767
Depreciation and amortization	188	297	—	—	—	—
Net cash from operating activities	(66,350)	(82,153)	(135,341)	(155,006)	(72,027)	(57,615)
Purchases of property and equipment	316	445	139	20	0	0
Net cash from investing activities	(316)	(445)	(139)	(20)	0	0
Proceeds from issuing common stock	255,785	100,993	—	27,032	—	—
Proceeds from issuing equity	—	—	—	—	39,688	58,142
Share repurchases	9,024	—	—	—	—	—
Proceeds from long-term debt	—	—	98,600	—	—	—
Repayments of long-term debt	—	—	—	—	2,500	0
Net cash from financing activities	247,359	102,447	96,237	26,522	36,660	56,518
Net change in cash	180,693	19,849	(39,243)	(128,504)	(35,367)	(1,097)

† Share count changed about 5x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
BioXcel Therapeutics	12,841	182	(6,098)*	31.3M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
Phio Pharmaceuticals	12,996	not reported	(4,035)*	11.6M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Palisade Bio	125,172	500	(7,603)*	174.3M	16.5 quarters	Q2 FY26 10-QJun 30, 2026
Citius Pharmaceuticals	17,008	1,494	(8,678)*	27.5M	2.0 quarters	Q3 FY26 10-QJun 30, 2026
Brainstorm Cell Therapeutics	22	not reported	(895)	11.0M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Cocrystal Pharma	2,169	105	(2,516)*	19.3M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Kiora Pharmaceuticals	7,077	not reported	(1,892)*	4.4M	8.9 quarters	Q2 FY26 10-QJun 30, 2026
Scienture Holdings	8,188	344	(3,132)*	41.1M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Cypherpunk Technologies	7,624	not reported	(2,692)*	107.8M	2.8 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.